SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 451.61 |
Enterprise Value ($M) | 464.18 |
Book Value ($M) | 24.45 |
Book Value / Share | 0.91 |
Price / Book | 18.47 |
NCAV ($M) | -9.62 |
NCAV / Share | -0.36 |
Price / NCAV | -46.93 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.08 |
Return on Assets (ROA) | -0.15 |
Return on Equity (ROE) | -0.30 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 1.43 |
Current Ratio | 1.97 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 49.96 |
Assets | 84.03 |
Liabilities | 59.58 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 39.01 |
Operating Income | -2.18 |
Net Income | -3.82 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.97 |
Cash from Investing | -40.01 |
Cash from Financing | 32.59 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | EcoR1 Capital, LLC | 7.70 | 41.74 | |
13G/A | Opaleye Management Inc. | 10.34 | 5.85 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
67,843 | 381,787 | 17.77 | |
59,390 | 392,301 | 15.14 | |
62,892 | 482,521 | 13.03 | |
236,551 | 885,127 | 26.73 | |
87,099 | 355,523 | 24.50 | |
(click for more detail) |
Similar Companies | |
---|---|
EOLS – Evolus, Inc. | ESPR – Esperion Therapeutics, Inc. |
ETNB – 89bio, Inc. | FATE – Fate Therapeutics, Inc. |
FHTX – Foghorn Therapeutics Inc. |
Financial data and stock pages provided by
Fintel.io